Reducing the Burden of HPV-related Cancers: Building Momentum in Primary Care

Post-Activity Test and Activity Evaluation

POST TEST

9‒14 year-olds

15‒24 year-olds

25‒34 year-olds

35‒45 year-olds

The rate of cervical cancer has decreased

The rate of cervical cancer has largely remained unchanged

The rate of oropharyngeal cancer in men has decreased

The rate of oropharyngeal cancer in men has largely remained unchanged

Adverse events are generally mild with injection site pain most commonly reported

Most common adverse events are headache and transient flu-like illness

Serious adverse events occur in about 5‒10% of recipients

The vaccine is contraindicated among those with egg allergy

No further HPV vaccination is needed

Administer one booster with 9vHPV

Finish the HPV series with 2 doses of 9vHPV vaccine

Restart the series with 3 doses of 9vHPV vaccine